Can Breast Cancer Develop During Pregnancy? Symptoms and Treatment
In this article
Pregnancy is a special time in a woman's life, but breast cancer can occasionally be diagnosed during it. Pregnancy-associated breast cancer (Gestational Breast Cancer) means breast cancer diagnosed during pregnancy, the first year after delivery or breastfeeding. Because both maternal and infant health are involved, diagnosis and treatment decisions require particular care.
Although uncommon, early diagnosis and appropriate management are crucial for maternal survival and infant health. Current studies indicate that standard protocols can be adapted to pregnancy, with outcomes generally similar to those outside pregnancy.
🔎 Symptoms
- A hard breast lump (the most important warning)
- Nipple retraction / distortion
- Skin thickening, dimpling or redness
- Axillary swelling (lymph node)
- Bloody nipple discharge
🧪 Diagnosis: Infant Safety First
Imaging
- Ultrasound (first choice)
- Noncontrast breast MRI (when needed)
- Chest X-ray (with abdominal lead shielding)
- Liver/bone: ultrasound or noncontrast MRI
Lymph Nodes
For clinically suspicious nodes, ultrasound + fine needle aspiration. Safety evidence for sentinel biopsy is growing; decisions require informed consent .
Distant Metastasis Assessment
Modified staging during pregnancy: shielded chest X-ray, liver ultrasound/MRI, and for bone, spinal MRI (without contrast).
🛠️ Treatment: Planning by Gestational Age
General Principle: Standards similar to those outside pregnancy, adapted to protect the fetus. Avoid unnecessary treatment delays.
- RT throughout pregnancy is deferred → until after delivery.
- Chemotherapy In the 2nd–3rd trimester: AC/FAC; taxanes (paclitaxel/docetaxel) in selected cases.
- Stop chemotherapy 3–4 weeks before delivery → reduce neonatal myelosuppression risk.
🩺 Surgery
- Mastectomy: May be preferred early in pregnancy because it can eliminate the need for RT.
- Breast-Conserving Surgery: Defer RT until postpartum.
- Axilla: Dissection is safe; sentinel biopsy has growing safety evidence.
☢️ Radiotherapy
During pregnancy, do not administer. Typical breast RT is 50–60 Gy; defer until delivery because of fetal exposure and malformation risk.
💊 Systemic Therapy
- AC / FAC protocols have extensive experience in the 2nd–3rd trimester.
- Taxanes: Increasing safety evidence in the literature (2nd–3rd trimester).
- Avoid: Trastuzumab, pertuzumab, T-DM1, lapatinib; tamoxifen/AIs; methotrexate.
🧩 Drug and Procedure Safety Matrix
| Treatment | 1st Trimester | 2nd–3rd Trimester | During Breastfeeding |
|---|---|---|---|
| AC / FAC | 🚫 | ✅ | 🚫 (during chemotherapy) |
| Taxanes | 🚫 | 🟡 (suitable for selected cases) | 🚫 (during chemotherapy) |
| Trastuzumab / HER2 agents | 🚫 | 🚫 | 🚫 |
| Tamoxifen / AI + LHRH | 🚫 | 🚫 | 🚫 (during breastfeeding) |
| Radiotherapy | 🚫 | 🚫 | ✅ (postpartum) |
☢️ Approximate Fetal Radiation Exposure
With breast RT of 50–60 Gy, fetal exposure in the first trimester may reach ~0.04–0.15 Gy, and in the third trimester, ~2 Gy . Malformation thresholds are considered to be <14 weeks: ~0.10–0.50 Gy, ≥14 weeks: at least ~0.50 Gy → do not give RT during pregnancy.
👶 Delivery Timing and Chemotherapy
- Plan delivery after the chemotherapy nadir has passed (lower infection/bleeding risk ↓).
- Stop chemotherapy 3–4 weeks before delivery.
- Prefer delivery after week ≥34 ; pulmonary maturity improves safety.
🍼 Breastfeeding
During Treatment
Chemotherapy / HER2 agents / endocrine treatment: during these, breastfeeding is not recommended.
After Treatment
Breastfeeding is generally safe. Lactation counseling improves success; milk production from the opposite breast is usually unaffected.
📈 Study Data
Among women delivering after treatment for early HR(+) disease, 63% of 313 patients breastfed.
Cumulative event incidence at 24 months: 3.6% (breastfeeding) vs 3.1% (not breastfeeding) → difference not significant.
📊 Effects on Pregnancy and the Infant
In a study of 129 children exposed to chemotherapy in the 2nd–3rd trimester, cardiac/cognitive/overall development was similar to peers.
In a cohort of 1170 cases, 88% of pregnancies resulted in live birth.
Preterm birth was more common, but ~90% was iatrogenic (planned for medical reasons).
🔮 Prognosis
- With standard, timely treatment for pregnancy-associated disease, survival is generally similar.
- Some series report worse outcomes after postpartum diagnosis (causality unclear).
- Terminating pregnancy does not improve survival; decisions should be individualized.
📌 Practical Summary
- A suspicious mass, even during pregnancy, should undergo biopsy without delay.
- Surgery in any trimester can be performed safely.
- No RT → postpone until postpartum.
- Chemotherapy: In the 2nd–3rd trimester, AC/FAC ± taxane; stop 3–4 weeks before delivery.
- HER2-targeted agents / tamoxifen / AIs → avoid during pregnancy and breastfeeding.
- Breastfeeding, after treatment ends, is generally safe; lactation counseling helps.
Sources
2. Loibl S, et al. Breast cancer diagnosed during pregnancy: incidence, treatment and prognosis. Lancet Oncol 2012;13:e274–e282.
3. Cardonick E, et al. Maternal and neonatal outcomes of anthracycline chemotherapy in pregnancy. J Clin Oncol 2010;28:327–333.
4. Lambertini M, et al. Long-term health outcomes of children exposed in utero to chemotherapy. Lancet Child Adolesc Health 2019;3:230–239.
5. Peccatori FA, et al. Breastfeeding after breast cancer: results from the POSITIVE trial. J Clin Oncol 2025
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.